Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Corvus Pharmaceuticals, Inc. (CRVS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results"
05/08/2023 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results"
05/05/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT"
11/01/2021 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results"
08/02/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results"
07/30/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
03/05/2020 8-K Quarterly results
10/29/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
05/09/2019 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
03/07/2019 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update BURLINGAME, Calif., March 07, 2019 -- Corvus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006, both as monotherapies and in combination with other agents and each other, positioning Corvus as a leader in the development of medicines that modulate the adenosine pathway,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In..."
11/01/2018 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
08/02/2018 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
05/03/2018 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
03/01/2018 8-K Quarterly results
Docs: "Investor Contact:"
11/02/2017 8-K Quarterly results
Docs: "Investor Contact:"
08/03/2017 8-K Quarterly results
Docs: "Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update"
05/04/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy